The US Justice Department announced on April 23 a significant shift in federal drug policy, reclassifying medical cannabis products from Schedule I to Schedule III under the Controlled Substances Act. This move places state-licensed or FDA-approved medical marijuana products alongside substances like Tylenol with codeine and anabolic steroids, which are considered to have legitimate medical applications, as reported by Politifact. Previously, cannabis was classified as a Schedule I drug, indicating no accepted medical use and a high potential for abuse.
While the Justice Department’s order marks a notable change in federal stance, its immediate practical effects are primarily on business operations and research, rather than outright federal legalization. As of June 2025, 40 states, three territories, and the District of Columbia had already legalized medical cannabis products, with 24 states, three territories, and D.C. also allowing or regulating non-medical cannabis uses.
Implications of Medical Cannabis Rescheduling
The reclassification of medical cannabis to Schedule III does not federally legalize cannabis for medicinal or recreational use. Instead, it addresses two key areas:
- Tax Benefits for Businesses: Under federal law, businesses dealing in Schedule I and II drugs cannot deduct standard business expenses due to Internal Revenue Code Section 280E. The new order makes state-licensed medical cannabis businesses eligible for such deductions, potentially allowing them to claim retroactive tax refunds for prior years, according to the IRS.
- Reduced Research Restrictions: The reclassification is expected to reduce administrative burdens for researchers studying cannabis. Researchers studying sanctioned medical cannabis products will no longer be in violation of federal law. Beau Kilmer, co-director of RAND’s Drug Policy Research Center, noted that this could encourage more researchers to study cannabis products available in commercial dispensaries, which some scientists previously found difficult to access or not representative of the market.
Despite these changes, the process is not without potential challenges. Anti-cannabis groups have indicated intentions to legally contest the reclassification. The Justice Department has scheduled a hearing for June 29 to consider rescheduling all cannabis products, both medical and otherwise.
Addressing Common Cannabis Misconceptions
The recent medical cannabis rescheduling has also brought to light several prevalent misconceptions about cannabis use:
Misconception: Federal Government Legalized Cannabis
The Justice Department’s reclassification is not federal legalization. It is a regulatory adjustment that primarily affects the tax treatment of medical cannabis businesses and streamlines research protocols. Federal prohibitions on cannabis possession, cultivation, and distribution remain in place for non-FDA-approved products or those not covered by a qualifying state license.
Misconception: Cannabis is Not Addictive
People can develop a cannabis use disorder, characterized by continued, uncontrolled use despite harmful consequences. Andrew Yockey, a University of Mississippi public health professor, stated that while many use cannabis without major issues, a
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
